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Background: We assessed the potential impact of infusion tubing on blood glucose imbalance in ICU patients
given intensive insulin therapy (IIT). We compared the incidence of blood glucose imbalance in patients equipped,
in a nonrandomized fashion, with either conventional tubing or with a multiport infusion device.
Methods: We retrospectively analyzed the nursing files of 35 patients given IIT through the distal line of a double-
lumen central venous catheter. A total of 1389 hours of IIT were analyzed for occurrence of hypoglycemic events
[defined as arterial blood glucose below 90 mg/dL requiring discontinuation of insulin].
Results: Twenty-one hypoglycemic events were noted (density of incidence 15 for 1000 hours of ITT). In 17 of
these 21 events (81%), medication had been administered during the previous hour through the line connected to
the distal lumen of the catheter. Conventional tubing use was associated with a higher density of incidence of
hypoglycemic events than multiport infusion device use (23 vs. 2 for 1,000 hours of IIT; rate ratio = 11.5; 95%
confidence interval, 2.71–48.8; p < 0.001).
Conclusions: The administration of on-demand medication through tubing carrying other medications can lead to
the delivery of significant amounts of unscheduled products. Hypoglycaemia observed during IIT could be related
to this phenomenon. The use of a multiport infusion device with a limited dead volume could limit hypoglycemia
in patients on IIT.
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During the past decade, there has been increasing recog-
nition of the challenge posed by optimization of glucose
management in the heterogeneous critically ill popula-
tion [1-4] The method, speed and degree of glycaemic
control, most importantly hypoglycaemia, are increas-
ingly recognized and debated [5-7]. Hypoglycemia oc-
curring during IIT has been associated with severity
score, ICU length of stay [8], outcome [6], inotropic* Correspondence: eric.maury@sat.aphp.fr
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in any medium, provided the original work is psupport [7] hemodialysis [9], and errors in administering
insulin [10]. We present a retrospective analysis of
hypoglycemic events in patients receiving continuously
infused insulin via a complex central venous catheter
(CVC) infusion set. We discuss concerns about the po-
tential for untoward bolus administration of insulin and
a method to limit its occurrence.Methods
This study was a retrospective analysis of the nursing
charts of patients admitted to a 14-bed ICU affiliated with
a 760-bed teaching hospital. We assessed the charts of all
consecutive nondiabetic patients during a 6-month period
(from 13th March to 13th September 2009) equipped withOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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intravenous therapies, including IIT through a double
CVC. The Institutional Review Board of our hospital
authorized this retrospective analysis. All patients or next
of kin gave their consent for the data obtained during their
ICU stay to be retrospectively analyzed.
In our ICU, during the study period, severely ill
patients receiving vasoactive agents were equipped with
a double-lumen CVC, through the proximal lumen of
which vasoactive agents (vasopressors and vasodilators)
were delivered. All remaining medications (antibiotics,
sedatives, diuretics, fluids, insulin) were administered
through the distal lumen. The tubing connected to the
distal lumen includes, from the infusion bag to the pa-
tient, a 175-cm infusion tube, a 45-cm DosiFlowW (Asept
Inmed, Balma France), a 20-cm 5-way valve ramp (Asept
Inmed), a 50-cm extension and a 45-cm 1-way tube con-
nected to the catheter (Figure 1). This tubing set-up
reflects the regular care adopted, during this period, by
the nursing team of our institution. During the study
period, the nursing team was offered the opportunity to
use a registered device (Edelvaiss 12 +R, Doran Intl,
Toussieu, France), a limited number of which were made
available by the Pharmacy Department of our institution.
Use of this multiport infusion device was intended to
simplify the administration of multiple medications
through the same catheter lumen. It offers multiport ac-
cess to an infusion tube connected to the distal lumen of
the CVC (Figure 2). The use of the multiport infusion
device was purely a nursing decision. Trialing of the new1
3
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Figure 1 The components (numbered in the order in which they were
other than vasoactive agents are administered via the distal lumen o
DosiFlowW [2], a 20-cm 5-way valve ramp [3], a 50-cm extension [4] adevice was contingent upon a requirement for complex
tubing (more than 2 medications infused through a
double-lumen CVC). To avoid severe hypoglycaemia, we
used a glycaemic control protocol less stringent than the
Leuven protocol [1]. Briefly, the purpose of our protocol
was to start intravenous insulin when blood glucose was
≥ 150 mg/dL. Insulin infusion (50 IU of Actrapid [Novo
Nordisk, Copenhagen, Denmark] in 50 mL of 0.9% so-
dium chloride) was started with the use of a pump (Per-
fusor-Space, B. Braun Medical, Boulogne, France) as
follows: 2 IU/h between 150 and 179 mg/dL, 3 IU/h be-
tween 180 and 219 mg/dL, 4 IU/h between 220 and
259 mg/dL, and 4 IU as a bolus and then 6 IU/h when
blood glucose was ≥ 260 mg/dL. Further insulin infusion
was adjusted according to blood glucose. When blood
glucose was ≤ 200 mg/dL and had decreased by ≥30 mg/
dL, insulin infusion was halved. Infusion was not modi-
fied when blood glucose was between 100 and 150 mg/
dL. Conversely, it was increased by 1 IU/h when blood
glucose was between 151 and 199 mg/dL or by 2 IU/h
when blood glucose ≥200 mg/dL. Insulin infusion was
stopped when blood glucose was ≤ 100 mg/dL and 30%
dextrose was given when blood glucose was ≤70 mg/dL.
Insulin was restarted when blood glucose was ≥ 130 mg/
dL. By comparison, in the Leuven protocol, insulin infu-
sion was started if the blood glucose level exceeded
110 mg/dL, and the infusion was adjusted to maintain
blood glucose between 80 and 110 mg/dL.
The features of hypoglycemic events while blood glu-
cose was stabilized were analyzed. Stabilized blood2
4
connected) of the infusion tubing through which medications
f the central venous catheter: a 175-cm infusion tube [1], a 45-cm
nd a 45-cm 1-way tube [5].
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Figure 2 Components of the multiport access device. Infusion tubing (1), 2-way ramp (2), distal multi-access port with a 0.6 mL dead
volume (3).
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for at least 3 hours in a patient receiving continuous en-
teral or parenteral nutrition. Hypoglycemic events were
defined as the occurrence, in a patient previously receiv-
ing 3 IU or more of intravenous insulin hourly, of arter-
ial blood glucose ≤ 90 mg/dL, for which insulin was
stopped. Mild hypoglycemic events were defined as the
impossibility of restarting insulin therapy for 2 hours;
moderate hypoglycemic events required discontinuation
of insulin for at least 3 hours. Blood glucose was initially
measured hourly and then every 4 hours when insulin
infusion was unmodified for 4 hours. Arterial blood glu-
cose was measured using an indwelling catheter inserted
for hemodynamic monitoring with the use of a hand-
held blood glucose meter (Accu-Chek Performa, Roche
Diagnostics France, Meylan, France). We compared
patients according to the tubing system used (conven-
tional tubing system or multiport infusion device) and
assessed the incidence of hypoglycemia associated with
the tubing system used.
Continuous variables are expressed as median with
quartile intervals and compared using the Mann–Whit-
ney U test. Categorical variables are compared using the
Chi-squared or Fisher’s exact test as appropriate. The
densities of hypoglycemic events for 1,000 hours of IIT
were compared using the rate ratio.
Results
During the study period, 35 of the 410 patients (23 men;
age, 59 years; SAPS II, 47) admitted to our ICU were en-
rolled in the analysis (Figure 3; Table 1). Thirty of themreceived both invasive mechanical ventilation and con-
tinuous intravenous sedation. Thirty-two received vaso-
pressors and three were given vasodilators through the
proximal lumen of the CVC. The median duration of
IIT was 42(extremes, 12–184 hours). A total of
1,389 hours of IIT was analyzed. The median number of
glucose measurements per day was 14(range, 8–22). The
number of glucose measurements per patient was simi-
lar in the two groups (13/day vs. 15/day). Mean blood
glucose level did not differ between the two groups:
161 ± 36 mg/dL in the group equipped with regular tub-
ing and 157 ± 32 mg/dL in the group equipped with the
multiport device. Twenty-one hypoglycemic events were
observed (incidence: 15 per 1,000 hours of IIT) as fol-
lows: 13 mild hypoglycemic events in 11 patients and 8
moderate hypoglycemic events in 7 patients. Blood glu-
cose was always ≥ 70 mg/dL in hypoglycemic events,
which did not require 30% dextrose. In 17 of these 21
hypoglycemic events (81%), the patient had been given,
during the hour before the hypoglycemic event, diuretics
(n = 5), antibiotics (n = 7) or a sedative bolus (n = 5)
through the line connected to the distal lumen. These
medications were infused in a bag of 50 or 100 mL con-
nected to the 5-way valve ramp. The measured dead vol-
ume from the 5-way valve ramp to the patient was
12.5 mL (range 12.0–13.1), whereas the measured dead
volume of the multiport infusion device was 0.6 mL
(range, 0.5–0.8).
The analysis of the hypoglycemic events showed that
their incidence was significantly decreased when the
multiport infusion device was used (23 vs. 2 for
Patients admitted in 
ICU during the study 
period 
n=410 





on vaso active agents 
n=75 
Patients equipped with a 
double lumen central 
venous catheter 
n=53 
Patients equipped with a 
double lumen central 
venous catheter and 
submitted to Intensive 
Insulin Therapy delivered 
through the distal lumen of 
the catheter : included 
n=35
Patients not submitted to 
Intensive Insulin Therapy 
 n=314 (including diabetics 
n=68)
Patients not on vaso 
active agents 
 n=21 
Patients not equipped with a 
double lumen catheter n=22 
[triple lumen (10), port-a-cath 
(8); multiple peripheral line (4)]
Insulin infusion delivered 
through a dedicated 
peripheral line  
n=18
Figure 3 Patient screening flow chart.
Table 1 Patient characteristics according to the device
used to administer medications through the distal lumen






Patients (n) 20 15
Sex ratio: M/F 11/9 12/3 0.16
Median age (yr) 58 60 0.2
SAPS II 45 48 0.4
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interval (CI), 2.71–48.8; p< 0.001; Table 1). Only one
mild hypoglycemic event was observed when the multi-
port infusion device was used. No medication infusion
was noted prior to this event.Mechanical ventilation 17/20 13/15 1
Days on mechanical
ventilation
10 [2–25] 11 [4–32] 0.8
ICU length of stay (days) 12 [7–25] 14 [9–32] 0.8
ICU mortality n (%) 8(30) 5(33) 1
Cumulative IIT duration (h) 863 526
IIT duration median
range (h)
48 [18–184] 36 [12–92] 0.06





incidence for 1000 h of IIT
23 2 <0.001Discussion
Hypoglycemia is the main side effect of IIT in ICU
patients [3-9], although there is little evidence that
hypoglycaemia results in poor outcome in critically ill
patients [3,11,12].
In this study, compared with classic tubing, the multi-
port infusion device was associated with a huge reduc-
tion in hypoglycemic events, possibly because of its low
dead space.
As recently suggested [13], when patients are given
IIT, care should be taken to use appropriate methods to:
1) infuse insulin (syringe-driven pump on a central line),and 2) measure blood glucose (prefer arterial to capillary
samples, use suitable measurement device). However, to
our knowledge no study has assessed the putative role of
infusion tubing. It also is intriguing to note that reports
of large multicenter, randomized, controlled trials asses-
sing the impact of IIT make no mention of the tubing
system used [1-4,12]. The present study suggests that for
patients on IIT and receiving multiple medications
through complex infusion tubing, blood glucose varia-
tions may occur after interventions involving the infu-
sion tubing, in the absence of any change in insulin
infusion rate.
When using complex tubing, bolus administration of
medication (sedation adjustment, antibiotic therapy,
diuretics) results in the delivery of all the solutes present
between the site of administration and the tip of the
catheter. In the present study, the measured volume of
solutes delivered to the patient in case of bolus adminis-
tration through the 5-way valve ramp was 12.5 mL.
Our study does, however, have several limitations.
First, it was a single-center, nonrandomized, retrospect-
ive analysis and has to be considered as a preliminary
study. Second, even though the impact of the device on
glycaemic control was not implicitly assessed, nurses
were asked to assess the new device’s use and acceptabil-
ity. We cannot therefore exclude that, when using this
new device, the nursing team provided a more intensive
level of care to the patient, leading to a more adequate
insulin delivery. Third, in contrast to the findings of
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observed in the present survey. This could be due in
part to our less stringent blood glucose target levels
compared with those of Van den Berghe et al. [1].
Fourth, the threshold of 90 mg/dL is not a usual value
used to define hypoglycemia during IIT and is neither
pertinent nor useful because it has no clinical implica-
tion. In fact, we chose this value and its definition not to
detect hypoglycemia but to detect glucose imbalance in
a patient who was previously in a steady state. We
sought to show that complex infusion tubing can modify
the accuracy of medication delivery. Insulin discontinu-
ation when blood glucose was below 90 mg/dL also
could explain in part the low rate of hypoglycemia that
we observed. We acknowledge that insulin interruption
is not a practice adopted by all intensivists prescribing
IIT worldwide, although it was part of the NICE-
SUGAR protocol [3]. Fifth, the shorter median duration
of IIT in the group of patients equipped with the multi-
port device could in part explain the difference in the in-
cidence of hypoglycemic events. As a matter of fact, the
duration of IIT has been associated with an increased in-
cidence of hypoglycemia [8]. However, this duration dif-
ference seems unlikely to be responsible for the
observed in incidence difference of hypoglycemic events.
Conclusion
The use of a multiport infusion device with a limited
dead space is associated with a lower incidence of
hypoglycemic events. This is probably related to the fact
that flushing of the tube contents is avoided with the
multiport infusion device. Physicians should be aware of
this phenomenon, which deserves further investigation.
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